CD8A and cancer: Importantly, FcγRIIB functions in a cell-autonomous manner to temper the CD8+ T cell response in the context of cancer, viral infection, and transplantation (20, 22, 23) and may limit patient response to immunotherapies such as immune checkpoint blockade (23).